It was very much as expected, but the following comments are most interesting: * no adverse events (most important for approval to sell) * accelerated review of 45 days for approval(makes first quarter look safe) * still anticipating commercial partner deal this month (this must mean all the due diligence and financing is complete, and agreement has been reached, leaving only formal completion)
I am very happy with the outlook, and see the remaining hurdles as relatively low risk.
The current selling of TIS I think must be a big buyer wanting to scare holders into selling. I won't be.
TIS Price at posting:
56.0¢ Sentiment: Buy Disclosure: Held
